Trastuzumab pamirtecan

帕康曲妥珠单抗

Report date: 2026/05/21 20:00:22

Base Information

Drug NameTrastuzumab pamirtecan
Drug Alias NameDB-1303BNT323
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Tetrapeptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > P1003 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsDNA topoisomerase I inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2DNA topoisomerase I
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesDuality Biologics (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesDuality Biologics (Suzhou) Co LtdBiaoentai (Shanghai) Pharmaceutical Co LtdDuality Biologics (Shanghai) Co Ltd +[6] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A